Trial Profile

Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Biomarker; Therapeutic Use

Most Recent Events

16 Nov 2020 Status changed from active, no longer recruiting to completed.
23 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
04 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com